



Local Ablation Therapy in Liver Cancer

Guest Editor:

Dr. Min Woo Lee

School of Medicine,
Sungkyunkwan University,
Suwon, Republic of Korea

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Local ablation therapy, including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, has been widely used as a curative treatment option for early-stage hepatocellular carcinoma (HCC) or small metastatic colorectal cancer in the liver. Recently, MWA has been emerging in the field of local ablation therapy because it has better physical properties by providing faster and higher heat than RFA. RFA has seen continuous evolution in the recent decade. Nowadays, centripetal RFA using multiple RF electrodes, even with the no-touch technique, is widely used for better local tumor control. Cryoablation is expected to produce comparable therapeutic outcomes to thermal ablation. Notably, cryoablation has been reported to have a lower complication rate in treating HCCs close to the bile duct or intrahepatic vessels than RFA. In this special issue, recent advances in local ablation therapy, including RFA, MWA, and cryoablation of liver cancer, will be updated.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)